Kingser BioTech announced its mid-term performance, with a net loss attributable to shareholders of $129 million, a year-on-year narrowing of 29.25%.

Kingstar Bio-Technology has released its interim results for the six months ending June 30, 2026, reporting revenues of $404 million, an increase of 27.35% year-on-year; the loss attributable to the companys shareholders narrowed by 29.25% to $129 million; with a loss per share of 5.92 cents. The announcement stated that the revenue increase was mainly driven by the rising industry demand for AI-driven drug discovery and antibody drug discovery, accelerating the growth of the "Gene to Protein" business; the strong recovery in upstream demand in the CRDMO industry contributed to an increase in project undertakings and improved capacity utilization; as well as the continued expansion of the industrial enzyme business, which contributed to stable sales growth during the reporting period.